Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5174489 | 0.81 | CYP3A4 (0.50) | CYP3A4MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2197570 | 0.80 | MAPT (0.50) | MAPK13MAPK12MAPK11MAPK14FLT1 | |
| SCHEMBL2199850 | 0.79 | MAPK13 (0.52) | CYP3A4MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL7035012 | 0.78 | CYP3A4 (0.48) | CYP3A4MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2198191 | 0.78 | SRD5A2 (0.47) | CYP3A4MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL7090488 | 0.77 | JAK2 (0.53) | CYP3A4JAK2TYK2CHRM2CHRM3 | |
| SCHEMBL5172393 | 0.77 | MAPK13 (0.61) | CYP3A4MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL8304975 | 0.77 | MAPK14 (0.47) | MAPK13MAPK12MAPK11MAPK14SMN1; SMN2 | |
| SCHEMBL2857233 | 0.76 | MAPK13 (0.52) | CYP3A4MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2197311 | 0.75 | MAPT (0.49) | CYP3A4MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658263-B9 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2011-11-09 | — | — | EP | disclosed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| CN-1826310-B | Novel aminobenzophenone compounds | LEO PHARMA AS | 2010-07-21 | — | — | CN | disclosed |
| EP-1658263-B1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2010-06-02 | — | — | EP | disclosed |
| CN-1826310-A | Novel aminobenzophenone compounds | LEO PHARMA AS (DK) | 2006-08-30 | — | — | CN | disclosed |
| US-20060166990-A1 | Novel aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-07-27 | — | — | US | disclosed |
| EP-1658263-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | Leo Pharma A/S (DK) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005009940-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA A/S (DK) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166990-A1 | Novel aminobenzophenone compounds | NFKBIA, UACA, ALDH7A1 | CYP3A4 613/4885MAPK13 1063/4885MAPK12 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.